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ABSTRACT 
Timolol is a non-selective beta-adrenergic antagonist that is similar to propranolol. The mechanism through which these 
drugs act on the regression of neovascularization is largely unknown. However, it is thought that the drugs may act 
through vascular endothelial growth factor signaling, vasoconstriction, and vascular endothelial cell apoptosis. The aim 
of this study was to determine the effect of timolol on corneal neovascularization in rabbits. Neovascularization was 
induced in the eyes of 20 rabbits. Next, the rabbits were divided into two groups: the timolol (experimental) group 
received eye drops containing timolol 0.5% twice per day; and the saline (control) group received saline drops twice per 
day for two weeks. After 7 days, the mean area of corneal neovascularization (presented as a percentage relative to 
baseline) was significantly lower in the timolol group than in the saline group (4.63 ± 4.61% versus 58.39 ± 6.31%, P < 
0.001). After 2 weeks, the mean area of corneal neovascularization was 0.85 ± 1.33% in the timolol group and 1.73 ± 
2.06% in the saline group (P = 0.315). After the first week of treatment, timolol significantly reduced the area of 
neovascularization compared to control. Timolol may increase the rate of recovery from corneal neovascularization. 
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INTRODUCTION
The cornea is transparent due to a complex balance 
between cellular components and layers of the cornea 
[1]. Angiogenesis is the process of growing new blood 
vessels from existing vessel structures. Corneal 
angiogenesis occurs due to various pathological 
conditions and can have a number of adverse effects [2]. 
Corneal neovascularization may be secondary to 
chemical burns, ischemia, infection, trauma, and 
inflamation [3]. Vascular endothelial growth factor 
(VEGF) has an important role in the pathogenesis of 
neovascularization. Therefore, theoretically, any drugs 
interfering with VEGF signaling can be used to prevent 
the process of neovascularization. In previous studies, 
the anti-VEGF drug, bevacizumab, was shown to have 
positive effects on retinal and corneal neovascularization 
[4-8]. Recent studies have shown that angiogenesis is 
controlled by the adrenergic system via pro-angiogenic 
factors. This process is similar to that of the effect of 
norepinephrine on VEGF upregulation. Non-selective 
beta-adrenergic antagonists can produce 
electroretinogram (ERG) changes, which are associated 
with phosphorylation of insulin-like growth factor 1 
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receptor (IGF-1R) and regulation of VEGF [9]. In recent 
years, propranolol was introduced as the standard 
treatment for hemangioma [10]. However, its systemic 
administration, especially in children, is associated with 
adverse reactions such as bronchospasm, hypotension, 
hypoglycemia, and congestive heart failure [11, 12]. 
Timolol is a non-selective beta-adrenergic antagonist that 
is similar to propranolol. It is available as a topical 
solution with a concentration of 0.25% or 0.5% and a gel 
with a concentration of 1% or 0.5% for the treatment of 
glaucoma or ocular hypertension [13, 14]. The 
mechanism via which these drugs act on the regression 
of neovascularization is largely unknown. However, it is 
thought that the drugs may act via VEGF signaling, 
vasoconstriction, and vascular endothelial cell apoptosis 
[14-16]. Propranolol has no effect on the normal values 
of VEGF in the retina, but timolol reduces VEGF levels in 
oxygen-induced retinopathy [9]. In this study, we aimed 
to determine the effect of timolol on corneal 
neovascularization in rabbits.  
MATERIALS AND METHODS 
Twenty Iranian male rabbits, weighing 1500 to 1900 g, 
were used in this study. Animals were individually 
housed in standard cages in rooms at 22 ± 2°C. For 
adaptation to the new environment, animals were fed 
for 1 week with pellet food and water as needed. They 
were used for research and only one eye per animal was 
tested. The Research Council of Ahwaz Jundishapur 
University (code IORC-9504) approved this study. Under 
local anesthesia with tetracaine eye drops (Sinadaro Lab, 
Tehran, Iran), the right eyes of all rabbits were prepared 
as follows.  
–
 
Figure 1: A: Three 7-0 Silk Sutures; B: Corneal Neovascularization prior to Treatment; C: Week 1 in the Saline Group; D: Week 1 in the Timolol Group; E: 
Week 2 in the Saline Group; E and F: Week 2 in the Timolol Group 
 
The eyelid was opened using an eye speculum and the 
eye was washed three times with 10 ml of normal saline. 
Then, three 7-0 silk sutures were placed radially at the 
pre-limbus in the upper region of the cornea at positions 
10, 12, and 2 at a depth of 50% that of corneal thickness 
(Fig 1A). 
The sutures were not buried. Ciprofloxacin eye drops 
(Sinadaro Lab. Tehran, Iran) were used to prevent 
infection and were continued for 2 weeks, three times a 
day. All sutures were placed in the same day by a single 
person. Two weeks after suture placement, all sutures 
were removed. Rabbits were randomly divided into two 
groups: the timolol (experimental) group received eye 
drops containing timolol 0.5% (Sinadaro Lab, Tehran, 
Iran) twice per day; and the saline (control) group 
received saline drops twice per day for two weeks. 
Immediately after removing the sutures, the first images 
of the cornea (representing early corneal 
neovascularization) were obtained (Fig 1B). 
Corneal neovascularization was imaged using Canon 
cameras with a magnification of 32 times. Photos were 
analyzed using ImageJ analysis software, version 49/1 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2017; 6(2)  
 
41 TIMOLOL INHIBITS CORNEAL NEOVASCULARIZATION 
(ImageJ 1.49 for Windows) [17]. To determine the 
percentage of corneal neovascularization, the number of 
pixels covering areas of corneal neovascularization was 
determined before and 1 and 2 weeks after treatment. 
The area of neovascularization at baseline (before 
treatment) was defined as 100% (Fig 1C–F). 
RESULTS 
After 1 week of treatment, the mean area of corneal 
neovascularization (presented as a percentage relative to 
baseline) was significantly lower in the timolol group 
than in the saline group (4.63 ± 4.61% versus 58.39 ± 
6.31%, P < 0.001). After 2 weeks of treatment, the mean 
area of corneal neovascularization was 0.85 ± 1.33% in 
the timolol group and 1.73 ± 2.06% in the saline group 
(not significantly different, P = 0.315) (Tables 1 and 2, 
Figs 2). The changes in area of corneal neovascularization 
from baseline to 2 weeks after treatment are shown in 
Table 2. After 2 weeks of treatment, the changes were 
not significantly different between the two groups. 
 
 
Table 1: The Area of Corneal Neovascularization at 1 and 2 Weeks after Treatment in the Two Groups 
puorG N Corneal neovascularization, % (mean ± standard deviation) 
  Week 1 Week 2 
Timolol 10 61.63 ± 4.4 33.85 ± 1.0 
Saline 10 31.39 ± 6.58 6.73 ± 2.1 
 
Table 2: The Mean Change in Corneal Neovascularization after Two Weeks of Treatment Compared to the Beginning of Treatment in Two Study Groups 
Group N Week 1 * Week 2 * 
Timolol 10 61.4 ± 95.37 33.1 ± 99.15 
Saline 10 31.6 ± 41.61 6.2 ± 98.27 
* Mean ± standard deviation 
 
 




This study investigated the effect of timolol on corneal 
neovascularization in rabbits. The results of this study 
suggest that compared to a saline control, timolol 
significantly reduced the area of corneal 
neovascularization at 1 week after treatment, but not at 
2 weeks. The effect of bevacizumab on corneal 
neovascularization inhibition was demonstrated by Kim 
et al. in 2008 [18] and Oner et al. in 2012 [19]. In 2011, 
Ristori and colleagues reported the role of propranolol as 
a beta-adrenergic antagonist in decreasing the 
expression of VEGF and IGF-1, thus preventing the 
development of retinal neovascularization. Further, they 
revealed for the first time that blockage of the beta-
adrenergic pathway protects against retinal angiogenesis 
and improves blood function in oxygen-induced 
retinopathy [9]. In 2014, Simavli and colleagues 
concluded that different doses of propranolol 
administered locally had a significant effect on corneal 
neovascularization in rats [20]. Earlier in 2008, Schwartz 
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and colleagues showed that topically delivered anti-
glaucoma drugs, namely latanoprost, dorzolamide, 
brimonidine, and timolol-malate may modify the normal 
angiogenic response in the rat cornea. Among the drugs 
used, prostaglandins revealed the most prominent pro-
angiogenic consequence [21]. The present study was 
partly able to show the effect of timolol in the 
improvement of corneal neovascularization. However, 
the final effect of timolol was not significant due to 
spontaneous recovery in the control group. The 
limitation of this study was mainly lack of variation in 
timolol dosage. 
CONCLUSIONS 
After the first week of treatment, timolol significantly 
reduced the area of neovascularization compared to 
control. Timolol increased the rate of recovery from 
corneal neovascularization. Topical timolol could be 
effective to prevent neovascularization. To confirm the 
effect of timolol, further studies with different dosages 
are required. 
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